Nachrichten zur Biogen Aktie

Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody

Biogens (BIIB) Qalsody is the first therapy approved to treat a rare genetic form of ALS in Europe…

Biogen Aktie: Sammelklage und Überwachung

Nach Vorwürfen bezüglich irreführender Angaben und Compliance-Verstößen sieht sich Biogen Inc., ein global agierendes biopharmazeutisches Unternehmen, mit einer Sammelklage sowie…

EU approves Biogen treatment for genetic form of ALS

…

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced the European Commission (EC) has…

Biogen Inc. (Nasdaq: BIIB) Investors Notice: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses.…

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm

The Schall Law Firm Encourages Investors in Biogen Inc. with Losses to Contact the Firm…

Verlustreicher Tag für Biogen-Aktionäre: Aktienkurs sinkt deutlich (195,4727 €)

Keinen Grund zur Freude haben Aktionäre von Biogen : Das Papier verliert deutlich an Wert. Das Wertpapier von Biogen gehört…

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm

NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Biogen Aktie: Sammelklage wegen Irreführung

Biogen, ein weltweit agierendes biopharmazeutisches Unternehmen, steht aktuell im Brennpunkt einer Sammelklage. Die Klage richtet sich gegen erfolgte Aktienkäufe des…

BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, May 25, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd…

Biogen Aktie: Klage und Umsatzrückgang

Biogen sieht sich mit einer Sammelklage konfrontiert, da Anleger in den USA Klage gegen das Unternehmen eingereicht haben. Die Beschwerde…

BIOGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Biogen Inc. and Encourages Investors to Contact the Firm

NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Stockholder Alert: Robbins LLP Informs Investors that a Shareholder Has Filed a Class Action Against Biogen Inc. (BIIB)

Robbins LLP is Investigating Allegations that Biogen Inc. (BIIB) Misled Investors Regarding its Financial Prospects…

BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.

BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against…

BIIB INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Biogen Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law…

Biogen erwirbt Human Immunology Biosciences - Aktienanalyse

Chicago (www.aktiencheck.de) - Biogen-Aktienanalyse von William Blair & Co: Myles Minter, Analyst von William Blair & Co, stuft die Aktie von…

Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline

Biogens (BIIB) acquisition of private biotech, HI-Bio, is set to expand its rare disease pipeline by adding the latters lead…

BIIB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead the Biogen Class Action Lawsuit

SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Biogen…

IGM Biosciences stock surges as Biogens deal for HI-Bio is seen as a positive By Investing.com

IGM Biosciences stock surges as Biogens deal for HI-Bio is seen as a positive…

Biogen: Übernahme von HI-Bio macht Sinn - Aktienanalyse

St. Louis (www.aktiencheck.de) - Biogen-Aktienanalyse von Stifel: Die Analysten von Stifel stufen die Aktie von Biogen Inc. (ISIN: US09062X1037, WKN: 789617,…

Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal

The move marks a sign the company is bulking up on rare disease medicines as its older multiple sclerosis drugs…

Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal By Reuters

Biogen to buy Human Immunology Biosciences in up to $1.8 billion deal…

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and…

ANLEIHEN-Woche KW20 - 2024: Ekosem-Agrar, BIOGENA, Booster Precision, Multitude, DMAF, Dt. Rohstoff, SANHA, PCC, Photon Energy, Metalcorp, LAIQON, pferdewetten, BMI, Singulus, Mutares, hep, Eleving, LEEF, UniDevice, …

Kalenderwoche 20 am KMU-Anleihemarkt (13. - 17. Mai 2024) - während die Börsen-Zeichnungsphase für die neue 10%-Premieren-Anleihe der NEON EQUITY…

ANLEIHEN-Woche KW20 - 2024: Ekosem-Agrar, BIOGENA, Booster, Multitude, DMAF, Dt. Rohstoff, SANHA, PCC, Photon Energy, Metalcorp, LAIQON, pferdewetten, BMI, Singulus, Mutares, hep, Eleving, LEEF, UniDevice, …

Kalenderwoche 20 am KMU-Anleihemarkt (13. - 17. Mai 2024) - während die Börsen-Zeichnungsphase für die neue 10%-Premieren-Anleihe der NEON EQUITY…

Biogen Aktie: Rückschlag bei Medikamentenentwicklung

Biogen und ein Pharmaunternehmen haben beschlossen, die Entwicklung eines vielversprechenden Medikaments gegen die amyotrophe Lateralsklerose (ALS) einzustellen, nachdem eine Studie…

Ionis (IONS), Biogen Down on Ending Development of ALS Drug

Ionis (IONS) and Biogen (BIIB) stop developing their experimental ALS drug after a phase I/II study failed to show improvement…

Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)

Stockholm, Sweden, May 15, 2024 – BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today said that they expect…

Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector

Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector…

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

TOKYO and CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito,…

dpa-AFX ProFeed